Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07309445 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States

Study acronym: Nova-sTAR
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Janssen Research & Development, LLC to Janssen Research & Development, LLC Completion pushed from Oct 9, 2029 to Jun 28, 2030 · Study sites: 17 to 19 · Eligibility criteria expanded, about 9 words · 1 more Show 4 more changesShow less
    • Completion pushed from Oct 9, 2029 to Jun 28, 2030
    • Study sites: 17 to 19
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 12 of 20 entries
  2. Study sites: 16 to 17v9
  3. Trial sites expanded: 13 → 16 locationsv8
  4. Trial sites expanded: 1 → 13 locations Start date changed from estimate of Jun 30, 2026 to Jun 12, 2026v7 Show 1 more changeShow less
    • Start date changed from estimate of Jun 30, 2026 to Jun 12, 2026
  5. Start date: May 1, 2026 to Jun 30, 2026v6
  6. Completion date: Oct 31, 2029 to Oct 9, 2029 Start date: Apr 30, 2026 to May 1, 2026v5 Show 1 more changeShow less
    • Start date: Apr 30, 2026 to May 1, 2026
  7. Completion pushed from Mar 31, 2029 to Oct 31, 2029 Start date: Apr 1, 2026 to Apr 30, 2026v4 Show 1 more changeShow less
    • Start date: Apr 1, 2026 to Apr 30, 2026
  8. Start date: Feb 27, 2026 to Apr 1, 2026v3
  9. Trial status: Not Yet Recruiting to Recruiting Start date: Dec 18, 2025 to Feb 27, 2026 · Study sites: 0 to 1v2 Show 2 more changesShow less
    • Start date: Dec 18, 2025 to Feb 27, 2026
    • Study sites: 0 to 1
  10. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Johnson & Johnson
289 trials monitored
See 17 trials at risk
Bladder Cancer
1,022 trials monitored
See 71 trials at risk
The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free survival) in participants with non-muscle invasive bladder cancer (NMIBC; an early-stage bladder cancer that is limited to the inner lining of bladder).
Trial Details
NCT Number NCT07309445
Lead Sponsor Janssen Research & Development, LLC
Conditions Non-Muscle Invasive Bladder Neoplasms
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov